Literature DB >> 26595812

Immune activation caused by vascular oxidation promotes fibrosis and hypertension.

Jing Wu, Mohamed A Saleh, Annet Kirabo, Hana A Itani, Kim Ramil C Montaniel, Liang Xiao, Wei Chen, Raymond L Mernaugh, Hua Cai, Kenneth E Bernstein, Jörg J Goronzy, Cornelia M Weyand, John A Curci, Natalia R Barbaro, Heitor Moreno, Sean S Davies, L Jackson Roberts, Meena S Madhur, David G Harrison.   

Abstract

Vascular oxidative injury accompanies many common conditions associated with hypertension. In the present study, we employed mouse models with excessive vascular production of ROS (tg(sm/p22phox) mice, which overexpress the NADPH oxidase subunit p22(phox) in smooth muscle, and mice with vascular-specific deletion of extracellular SOD) and have shown that these animals develop vascular collagen deposition, aortic stiffening, renal dysfunction, and hypertension with age. T cells from tg(sm/p22phox) mice produced high levels of IL-17A and IFN-γ. Crossing tg(sm/p22phox) mice with lymphocyte-deficient Rag1(-/-) mice eliminated vascular inflammation, aortic stiffening, renal dysfunction, and hypertension; however, adoptive transfer of T cells restored these processes. Isoketal-protein adducts, which are immunogenic, were increased in aortas, DCs, and macrophages of tg(sm/p22phox) mice. Autologous pulsing with tg(sm/p22phox) aortic homogenates promoted DCs of tg(sm/p22phox) mice to stimulate T cell proliferation and production of IFN-γ, IL-17A, and TNF-α. Treatment with the superoxide scavenger tempol or the isoketal scavenger 2-hydroxybenzylamine (2-HOBA) normalized blood pressure; prevented vascular inflammation, aortic stiffening, and hypertension; and prevented DC and T cell activation. Moreover, in human aortas, the aortic content of isoketal adducts correlated with fibrosis and inflammation severity. Together, these results define a pathway linking vascular oxidant stress to immune activation and aortic stiffening and provide insight into the systemic inflammation encountered in common vascular diseases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26595812      PMCID: PMC4701546          DOI: 10.1172/JCI80761

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  48 in total

1.  Role of vascular extracellular superoxide dismutase in hypertension.

Authors:  Heinrich E Lob; Antony Vinh; Li Li; Yelena Blinder; Stefan Offermanns; David G Harrison
Journal:  Hypertension       Date:  2011-07-05       Impact factor: 10.190

2.  Carbamylation-dependent activation of T cells: a novel mechanism in the pathogenesis of autoimmune arthritis.

Authors:  Piotr Mydel; Zeneng Wang; Mikael Brisslert; Annelie Hellvard; Leif E Dahlberg; Stanley L Hazen; Maria Bokarewa
Journal:  J Immunol       Date:  2010-05-19       Impact factor: 5.422

3.  Interleukin-17A stimulates cardiac fibroblast proliferation and migration via negative regulation of the dual-specificity phosphatase MKP-1/DUSP-1.

Authors:  Anthony J Valente; Tadashi Yoshida; Jason D Gardner; Naveen Somanna; Patrice Delafontaine; Bysani Chandrasekar
Journal:  Cell Signal       Date:  2011-10-20       Impact factor: 4.315

4.  Inhibition and genetic ablation of the B7/CD28 T-cell costimulation axis prevents experimental hypertension.

Authors:  Antony Vinh; Wei Chen; Yelena Blinder; Daiana Weiss; W Robert Taylor; Jörg J Goronzy; Cornelia M Weyand; David G Harrison; Tomasz J Guzik
Journal:  Circulation       Date:  2010-11-29       Impact factor: 29.690

5.  High-throughput quantification of hydroxyproline for determination of collagen.

Authors:  Kathleen Hofman; Bronwyn Hall; Helen Cleaver; Susan Marshall
Journal:  Anal Biochem       Date:  2011-06-22       Impact factor: 3.365

6.  Tocilizumab monotherapy reduces arterial stiffness as effectively as etanercept or adalimumab monotherapy in rheumatoid arthritis: an open-label randomized controlled trial.

Authors:  Kensuke Kume; Kanzo Amano; Susumu Yamada; Kazuhiko Hatta; Hiroyuki Ohta; Noriko Kuwaba
Journal:  J Rheumatol       Date:  2011-08-01       Impact factor: 4.666

7.  Interferon-γ signaling inhibition ameliorates angiotensin II-induced cardiac damage.

Authors:  Lajos Markó; Heda Kvakan; Joon-Keun Park; Fatimunnisa Qadri; Bastian Spallek; Katrina J Binger; Edward P Bowman; Markus Kleinewietfeld; Verena Fokuhl; Ralf Dechend; Dominik N Müller
Journal:  Hypertension       Date:  2012-10-29       Impact factor: 10.190

8.  Aortic stiffness, blood pressure progression, and incident hypertension.

Authors:  Bernhard M Kaess; Jian Rong; Martin G Larson; Naomi M Hamburg; Joseph A Vita; Daniel Levy; Emelia J Benjamin; Ramachandran S Vasan; Gary F Mitchell
Journal:  JAMA       Date:  2012-09-05       Impact factor: 56.272

9.  Interleukin 17 promotes angiotensin II-induced hypertension and vascular dysfunction.

Authors:  Meena S Madhur; Heinrich E Lob; Louise A McCann; Yoichiro Iwakura; Yelena Blinder; Tomasz J Guzik; David G Harrison
Journal:  Hypertension       Date:  2009-12-28       Impact factor: 10.190

10.  Tumor necrosis factor-alpha antagonists improve aortic stiffness in patients with inflammatory arthropathies: a controlled study.

Authors:  Kristin Angel; Sella Aarrestad Provan; Hanne Løvdahl Gulseth; Petter Mowinckel; Tore Kristian Kvien; Dan Atar
Journal:  Hypertension       Date:  2009-12-28       Impact factor: 10.190

View more
  81 in total

1.  CD28/B7 Deficiency Attenuates Systolic Overload-Induced Congestive Heart Failure, Myocardial and Pulmonary Inflammation, and Activated T Cell Accumulation in the Heart and Lungs.

Authors:  Huan Wang; Dongmin Kwak; John Fassett; Lei Hou; Xin Xu; Brandon J Burbach; Thenappan Thenappan; Yawei Xu; Jun-Bo Ge; Yoji Shimizu; Robert J Bache; Yingjie Chen
Journal:  Hypertension       Date:  2016-07-18       Impact factor: 10.190

Review 2.  Strategies for Achieving Healthy Vascular Aging.

Authors:  Kristen L Nowak; Matthew J Rossman; Michel Chonchol; Douglas R Seals
Journal:  Hypertension       Date:  2018-01-08       Impact factor: 10.190

3.  Modeling mechano-driven and immuno-mediated aortic maladaptation in hypertension.

Authors:  Marcos Latorre; Jay D Humphrey
Journal:  Biomech Model Mechanobiol       Date:  2018-06-07

Review 4.  Hypertension as an autoimmune and inflammatory disease.

Authors:  Yalcin Solak; Baris Afsar; Nosratola D Vaziri; Gamze Aslan; Can Ege Yalcin; Adrian Covic; Mehmet Kanbay
Journal:  Hypertens Res       Date:  2016-04-07       Impact factor: 3.872

Review 5.  Inflammation as a mediator of arterial ageing.

Authors:  Daniel W Trott; Paul J Fadel
Journal:  Exp Physiol       Date:  2019-08-08       Impact factor: 2.969

Review 6.  Hypertension in HIV-Infected Adults: Novel Pathophysiologic Mechanisms.

Authors:  Sasha A Fahme; Gerald S Bloomfield; Robert Peck
Journal:  Hypertension       Date:  2018-05-18       Impact factor: 10.190

Review 7.  Mechanisms of isolevuglandin-protein adduct formation in inflammation and hypertension.

Authors:  Liang Xiao; David M Patrick; Luul A Aden; Annet Kirabo
Journal:  Prostaglandins Other Lipid Mediat       Date:  2018-09-29       Impact factor: 3.072

Review 8.  Role of the Immune System in Hypertension.

Authors:  Bernardo Rodriguez-Iturbe; Hector Pons; Richard J Johnson
Journal:  Physiol Rev       Date:  2017-07-01       Impact factor: 37.312

9.  Loss of Resistance to Angiotensin II-Induced Hypertension in the Jackson Laboratory Recombination-Activating Gene Null Mouse on the C57BL/6J Background.

Authors:  Hong Ji; Amrita V Pai; Crystal A West; Xie Wu; Robert C Speth; Kathryn Sandberg
Journal:  Hypertension       Date:  2017-04-24       Impact factor: 10.190

10.  Tributyltin chloride disrupts aortic vascular reactivity and increases reactive oxygen species production in female rats.

Authors:  Carolina Falcão Ximenes; Samya Mere Lima Rodrigues; Priscila Lang Podratz; Eduardo Merlo; Julia Fernandez Puñal de Araújo; Lívia Carla Melo Rodrigues; Juliana Barbosa Coitinho; Dalton Valentim Vassallo; Jones Bernardes Graceli; Ivanita Stefanon
Journal:  Environ Sci Pollut Res Int       Date:  2017-09-13       Impact factor: 4.223

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.